S104: DIFFERENTIAL TARGET PROFILES AND EFFICACY OF ADCLEC.SYN1 AND CD33-CARS IN HUMANIZED AML MODELS

• Sascha Haubner,
• Jorge Mansilla-Soto,
• Sarah Nataraj,
• Friederike Kogel,
• Qing Chang,
• Elisa de Stanchina,
• Michael Lopez,
• Kathryn Fraser,
• Jae Park,
• Xiuyan Wang,
• Isabelle Rivière,
• Michel Sadelain

Affiliations

Sascha Haubner

1 Memorial Sloan Kettering Cancer Center, Center for Cell Engineering, New York, United States

Jorge Mansilla-Soto

1 Memorial Sloan Kettering Cancer Center, Center for Cell Engineering, New York, United States

Sarah Nataraj

1 Memorial Sloan Kettering Cancer Center, Center for Cell Engineering, New York, United States

Friederike Kogel

1 Memorial Sloan Kettering Cancer Center, Center for Cell Engineering, New York, United States

Qing Chang

2 Memorial Sloan Kettering Cancer Center, Antitumor Assessment Core Facility, New York, United States

Elisa de Stanchina

2 Memorial Sloan Kettering Cancer Center, Antitumor Assessment Core Facility, New York, United States

Michael Lopez

1 Memorial Sloan Kettering Cancer Center, Center for Cell Engineering, New York, United States

Kathryn Fraser

3 Takeda Development Center Americas, Inc., Lexington, United States

Jae Park

4 Memorial Sloan Kettering Cancer Center, Leukemia Service, Department of Medicine, New York, United States

Xiuyan Wang

5 Memorial Sloan Kettering Cancer Center, Cell Therapy and Cell Engineering Facility, New York, United States

Isabelle Rivière

5 Memorial Sloan Kettering Cancer Center, Cell Therapy and Cell Engineering Facility, New York, United States

Michel Sadelain

1 Memorial Sloan Kettering Cancer Center, Center for Cell Engineering, New York, United States